ProHealth health Vitamin and Natural Supplement Store and Health
Home  |  Log In  |  My Account  |  View Cart  View Your ProHealth Vitamin and Supplement Shopping Cart
800-366-6056  |  Contact Us  |  Help
Facebook Google Plus
Fibromyalgia  Chronic Fatigue Syndrome & M.E.  Lyme Disease  Natural Wellness  Supplement News  Forums  Our Story
Store     Brands   |   A-Z Index   |   Best Sellers   |   New Products   |   Deals & Specials   |   Under $10   |   SmartSavings Club

Trending News

SURVEY: Cognitive Impairment II

Top 3 Nutrients to Detox the Liver and Soothe Digestion

Natural Bladder Control, Go Less and Live More

Study bodes well for low-carb eaters

Top Vitamin and Mineral Deficiencies — Are You at Risk?

Vital Molecule Increases Cellular Energy and Improves Cognitive Function

Omega Fix for Obesity: How the Right Fats Fight Fat

Potential of Quercetin in the Treatment of Melanoma

How Pomegranate May Protect Against Cancer

Trimming the spare tire: Canola oil may cut belly fat

 
Print Page
Email Article

Trial of Eszopiclone (Lunesta®) for Insomnia & Other FM Symptoms

  [ 559 votes ]   [ Discuss This Article ]
By Editor • www.ProHealth.com • February 2, 2007


A Phase IV study at Robert Wood Johnson Medical School in Piscataway, New Jersey, is testing the sleep drug eszopiclone (Lunesta®) for the treatment of insomnia and other symptoms of Fibromyalgia. The trial, sponsored by Sepracor, Inc., is recruiting Fibromyalgia patients of both sexes between the ages of 18 and 64.

Study Purpose and Hypothesis
“Although the pathophysiology of FM is not yet well-understood, sleep disturbance is a prominent feature of most theories. Eszopiclone has been approved by the FDA for the treatment of insomnia, but has not been studied in the treatment of FMS. The purpose is to assess the efficacy of eszopiclone for the treatment of insomnia and other symptoms of Fibromyalgia (FMS) in FMS patients. Participants will be randomly selected to receive eszopiclone or placebo. It is hypothesized that participants receiving eszopiclone will report greater improvement in total sleep time, sleep quality, pain, fatigue, physical functioning, and emotional distress than will those receiving placebo (fake dose).

Study Type: Interventional
Study Design: Treatment, Randomized, Double-Blind, Placebo Control, Parallel Assignment, Efficacy Study
Official Title: “Eszopiclone in the Treatment of Insomnia and Associated Symptoms of Fibromyalgia” (ClinicalTrials.com number NCT00392041)

Primary Outcome to Be Measured
n Total sleep time (TST) as recorded in patient diaries

Secondary Outcomes to Be Measured
n Wake time after sleep onset (WASO)
n Sleep quality
n Clinician-rated overall severity of Fibromyalgia
n Fibromyalgia Impact Questionnaire

Requirements for Inclusion:
n Male or female, age 18 through 64.
n Meets ACR criteria for FMS, as determined by rheumatological examination and a medical history review.
n Reports sleep maintenance insomnia (total sleep time of < 6.5 hours or sleep impairment consisting of 3 of 7 nights per week for a month by history) or sleep onset latency insomnia (at least 3 of 7 nights of sleep latency > 30 minutes), as well as clinically significant daytime distress or impairment during the 1 week self assessment prior to baseline.
n Has completed 8th grade and is fluent in English.
n If a female of child bearing potential, the patient must be non-pregnant and either post-menopausal or using an approved birth control method. Acceptable birth control methods include: history of tubal ligation, having a male partner who is sterile, IUDs, birth control pills or other hormonal birth control methods (e.g., birth control patch, Depo-Provera injections), and double-barrier methods (e.g., condom and foam).
n Antidepressant medication will be allowed if the patient has been on a stable dose for at least one month.

Exclusion Criteria:
n Evidence of traumatic injury, inflammatory rheumatic disease, or infectious or endocrine-related arthropathy.
n Evidence of a primary sleep disorder (e.g., significant sleep disordered breathing (central or obstructive apnea), periodic limb movement disorder, or REM sleep behavior disorder.
n Any current, clinically significant medical condition.
n Pregnancy.
n Meets DSM-IV criteria for bipolar disorder, psychotic disorder, organic brain syndrome, or psychoactive substance abuse or dependence.
n Any current psychiatric disorder that would interfere with study participation (investigator judgment).
n Active suicidal ideation.
n Plans to engage in additional psychotherapy during the study.
n Concurrent use of benzodiazepines after 6pm or as a sleep aid.
n Concurrent use of any other sleep aid.
n Concurrent use of analgesics other than acetaminophen or non-steroidal anti-inflammatory medication.
n Concurrent use of any medication that has not been stabilized for at least 1 month prior to screening.

Location and Contact Information
Please refer to this study by ClinicalTrials.gov identifier NCT00392041

Department of Psychiatry, University of Medicine and Dentistry New Jersey
(UMDNJ)-Robert Wood Johnson Medical School, Piscataway, New Jersey

Prinical Investigator Lesley A. Allen, PhD 732-235-4412
allenla@umdnj.edu Jade Tiu, B.A. 732-235-3378
tiuje@umdnj.edu

Health Authority: United States Institutional Review Board




Post a Comment

Featured Products From the ProHealth Store
FibroSleep™ Optimized Curcumin Longvida® Vitamin D3 Extreme™


Article Comments



Be the first to comment on this article!

Post a Comment


 
Natural Pain Relief Supplements

Featured Products

Vitamin D3 Extreme™ Vitamin D3 Extreme™
50,000 IU Vitamin D3 - Prescription Strength
Optimized Curcumin Longvida® Optimized Curcumin Longvida®
Supports Cognition, Memory & Overall Health
FibroSleep™ FibroSleep™
The All-in-One Natural Sleep Aid
Ultra ATP+, Double Strength Ultra ATP+, Double Strength
Get energized with malic acid & magnesium
Ultra EPA  - Fish Oil Ultra EPA - Fish Oil
Ultra concentrated source of essential fish oils

Natural Remedies

Complete and Natural Menopause Relief Complete and Natural Menopause Relief
D-ficient? Health Risks You Need to Know About D-ficient? Health Risks You Need to Know About
Live Without Anxiety or Stress Live Without Anxiety or Stress
Cell-Charging Compound Gives Steady Energy to Fibromyalgia & Chronic Fatigue Patients Cell-Charging Compound Gives Steady Energy to Fibromyalgia & Chronic Fatigue Patients
Nutrients to Combat the Modern Stress Epidemic Nutrients to Combat the Modern Stress Epidemic

CONTACT US
ProHealth, Inc.
555 Maple Ave
Carpinteria, CA 93013
(800) 366-6056  |  Email

· Become a Wholesaler
· Vendor Inquiries
· Affiliate Program
SHOP WITH CONFIDENCE
Credit Card Processing
SUBSCRIBE TO OUR NEWSLETTERS
Get the latest news about Fibromyalgia, M.E/Chronic Fatigue Syndrome, Lyme Disease and Natural Wellness

CONNECT WITH US ProHealth on Facebook  ProHealth on Twitter  ProHealth on Pinterest  ProHealth on Google Plus

© 2016 ProHealth, Inc. All rights reserved. Pain Tracker App  |  Store  |  Customer Service  |  Guarantee  |  Privacy  |  Contact Us  |  Library  |  RSS  |  Site Map